Literature DB >> 28577946

Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.

Michael Ziemke1, Tejas Patil2, Kyle Nolan1, Darinee Tippimanchai1, Stephen P Malkoski3.   

Abstract

OBJECTIVE: Smad4 is a tumor suppressor that transduces transforming growth factor beta signaling and regulates genomic stability. We previously found that Smad4 knockdown in vitro inhibited DNA repair and increased sensitivity to DNA topoisomerase inhibitors. In this study, we assessed the association between reduced Smad4 expression and DNA topoisomerase inhibitor sensitivity in human non-small cell lung cancer (NSCLC) patients and evaluated the relationship between genomic alterations of Smad4 and molecular alterations in DNA repair molecules.
MATERIALS AND METHODS: We retrospectively identified NSCLC patients who received etoposide or gemcitabine. Chemotherapeutic response was quantified by RECIST 1.1 criteria and Smad4 expression was assessed by immunohistochemistry. Relationships between Smad4 mutation and DNA repair molecule mutations were evaluated using publically available datasets.
RESULTS: We identified 28 individuals who received 30 treatments with gemcitabine or etoposide containing regimens for NSCLC. Reduced Smad4 expression was seen in 13/28 patients and was not associated with significant differences in clinical or pathologic parameters. Patients with reduced Smad4 expression had a larger response to DNA topoisomerase inhibitor containing regimens then patients with high Smad4 expression (-25.7% vs. -6.8% in lesion size, p=0.03); this relationship was more pronounced with gemcitabine containing regimens. The overall treatment response was higher in patients with reduced Smad4 expression (8/14 vs 2/16 p=0.02). Analysis of data from The Cancer Genome Atlas revealed that Smad4 mutation or homozygous loss was mutually exclusive with genomic alterations in DNA repair molecules.
CONCLUSIONS: Reduced Smad4 expression may predict responsiveness to regimens that contain DNA topoisomerase inhibitors. That Smad4 signaling alterations are mutually exclusive with alterations in DNA repair machinery is consistent with an important role of Smad4 in regulating DNA repair.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemosensitivity; DNA damage; Lung cancer; Smad4; TGFβ

Mesh:

Substances:

Year:  2017        PMID: 28577946      PMCID: PMC5501281          DOI: 10.1016/j.lungcan.2017.04.017

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  38 in total

Review 1.  TGFβ signalling in context.

Authors:  Joan Massagué
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09-20       Impact factor: 94.444

Review 2.  New and emerging targeted treatments in advanced non-small-cell lung cancer.

Authors:  Fred R Hirsch; Kenichi Suda; Jacinta Wiens; Paul A Bunn
Journal:  Lancet       Date:  2016-09-01       Impact factor: 79.321

3.  Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.

Authors:  Giorgio Scagliotti; Thomas Brodowicz; Frances A Shepherd; Christoph Zielinski; Johan Vansteenkiste; Christian Manegold; Lorinda Simms; Frank Fossella; Katherine Sugarman; Chandra P Belani
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

4.  Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb.

Authors:  A B Glick; W C Weinberg; I H Wu; W Quan; S H Yuspa
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

Review 5.  Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer.

Authors:  Stephen P Malkoski; Xiao-Jing Wang
Journal:  FEBS Lett       Date:  2012-02-03       Impact factor: 4.124

6.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

7.  Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.

Authors:  Nicolas Girard; Pascale Jacoulet; Marie Gainet; Rami Elleuch; Didier Pernet; Alain Depierre; Jean-Charles Dalphin; Virginie Westeel
Journal:  J Thorac Oncol       Date:  2009-12       Impact factor: 15.609

8.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

9.  Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage.

Authors:  Noritaka Adachi; Sairei So; Hideki Koyama
Journal:  J Biol Chem       Date:  2004-06-24       Impact factor: 5.157

10.  Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors.

Authors:  Sarah M Haeger; Joshua J Thompson; Sean Kalra; Timothy G Cleaver; Daniel Merrick; Xiao-Jing Wang; Stephen P Malkoski
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

View more
  6 in total

Review 1.  Lessons learned from SMAD4 loss in squamous cell carcinomas.

Authors:  Ariel L Hernandez; Christian D Young; Jing H Wang; Xiao-Jing Wang
Journal:  Mol Carcinog       Date:  2019-05-29       Impact factor: 4.784

2.  SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer.

Authors:  Yue Wang; Qianqian Xue; Qiang Zheng; Yan Jin; Xuxia Shen; Mu Yang; Xiaoyan Zhou; Yuan Li
Journal:  Lab Invest       Date:  2020-12-10       Impact factor: 5.662

Review 3.  Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?

Authors:  Fabrice Tolle; Viktor Umansky; Jochen Utikal; Stephanie Kreis; Sabrina Bréchard
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

4.  Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models.

Authors:  Kyle Nolan; Gregory Verzosa; Tim Cleaver; Darinee Tippimanchai; Lisa N DePledge; Xiao-Jing Wang; Christian Young; Anh Le; Robert Doebele; Howard Li; Stephen P Malkoski
Journal:  Cancer Cell Int       Date:  2020-08-28       Impact factor: 5.722

5.  Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma.

Authors:  Raul Caso; James G Connolly; Jian Zhou; Kay See Tan; James J Choi; Gregory D Jones; Brooke Mastrogiacomo; Francisco Sanchez-Vega; Bastien Nguyen; Gaetano Rocco; Daniela Molena; Smita Sihag; Prasad S Adusumilli; Matthew J Bott; David R Jones
Journal:  NPJ Precis Oncol       Date:  2021-07-21

Review 6.  Clinicopathological and Molecular Characteristics of Colorectal Signet Ring Cell Carcinoma: A Review.

Authors:  Yang An; Jiaolin Zhou; Guole Lin; Huanwen Wu; Lin Cong; Yunhao Li; Xiaoyuan Qiu; Weikun Shi
Journal:  Pathol Oncol Res       Date:  2021-07-26       Impact factor: 3.201

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.